Human VEGF165-myoblasts produce concomitant angiogenesis/myogenesis in the regenerative heart.
Bioengineering the regenerative heart may provide a novel treatment for heart failure. On May 14, 2002, a 55-year-old man suffering from ischemic myocardial infarction received 25 injections carrying 465 million cGMP-produced pure myoblasts into his myocardium after coronary artery bypass grafting. As on August 28, 2002, his EKG was normal and showed no arrhythmia. His ejection fraction increased by 13%. He no longer experienced shortness of breath and angina as he did before the treatment. Three myogenesis mechanisms were elucidated with 17 human/porcine xenografts using cyclosporine as immunosuppressant. Some myoblasts developed to become cardiomyocytes. Others transferred their nuclei into host cardiomyocytes through natural cell fusion. As yet others formed skeletal myofibers with satellite cells. De novo production of contractile filaments augmented the heart contractility. Human myoblasts transduced with VEGF165 gene produced six times more capillaries in porcine myocardium than in placebo. Xenograft rejection was not observed for up to 20 weeks despite cyclosporine discontinuation at 6 weeks. Pros and cons of autografts vs. allografts are compared to guide future development of heart cell therapy.
Law
Peter K
PK
Cell Therapy Research Foundation, Memphis, TN, USA. peter@celltherapy.com
Haider
Kh
Kh
Fang
G
G
Jiang
S
S
Chua
F
F
Lim
Y T
YT
Sim
E
E
D000818:Animals; D006321:Heart / Q000502:physiology*; D006801:Humans; D007763:Lac Operon; D024510:Muscle Development; D032386:Myoblasts, Cardiac / Q000378:metabolism* / Q000637:transplantation*; D009206:Myocardium / Q000378:metabolism / Q000648:ultrastructure; D018919:Neovascularization, Physiologic; D012038:Regeneration / Q000502:physiology; D013552:Swine; D014161:Transduction, Genetic; D014183:Transplantation, Heterologous; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics* / Q000502:physiology
C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A